Quadrivalent Market Report 2025

The quadrivalent market size has grown strongly in recent years. It will grow from $8.87 billion in 2024 to $9.61 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to disease complexity, educational initiatives, past health events, healthcare growth, technological progress.

The quadrivalent market size is expected to see rapid growth in the next few years. It will grow to $14.22 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to global health events, competitive dynamics, educational campaigns, regulatory changes, evolving disease patterns. Major trends in the forecast period include disease prevalence, regulatory environment, healthcare infrastructure, consumer awareness and education, competitive landscape.

The increasing prevalence of chronic and infectious diseases is anticipated to drive the growth of the quadrivalent market in the future. A chronic disease is a long-term condition resulting from genetics and lifestyle, while an infectious disease is any illness caused by an infectious agent such as a virus, bacteria, fungus, or protozoan. Quadrivalent vaccines play a crucial role in preventing morbidity and mortality from serious infections, as well as addressing diseases beyond the specific infections they are designed to combat. These vaccines are also utilized to prevent chronic (non-communicable) diseases when infectious agents contribute to carcinogenesis. For instance, in September 2024, a report from the Centers for Disease Control and Prevention, a non-profit organization based in the U.S., indicated that in Week 37, 0.5% of specimens tested positive for influenza, with 91.4% being influenza A and 8.6% influenza B. Cumulatively, since October 1, 2023 (Week 40), 8.7% of specimens tested positive, with 69.2% being influenza A and 30.8% influenza B, reflecting a higher overall positivity rate and an increasing proportion of influenza B cases over time. Therefore, the rising prevalence of chronic and infectious diseases is driving the growth of the quadrivalent market.

The expected growth in the quadrivalent market is also fueled by the global expansion of immunization coverage. Immunization coverage, indicating the proportion of a population receiving specific vaccines within a defined period, drives increased demand for vaccines. Quadrivalent vaccines, protecting against four strains, are often integrated into routine vaccination programs to combat multiple disease threats in a single shot. The World Health Organization reported an improvement in the number of zero-dose children, decreasing from 18.1 million in 2021 to 14.3 million in 2022. Moreover, global coverage for the initial dose of the human papillomavirus (HPV) vaccine in girls increased from 16% in 2021 to 21% in 2022. Thus, the rising global immunization coverage is expected to propel the quadrivalent market forward.

A key trend gaining prominence in the quadrivalent market is product innovation. Major companies in the sector are actively developing innovative solutions to reinforce their market positions. AstraZeneca, a UK-based pharmaceutical company, launched FluMist quadrivalent (Influenza Vaccination Live, Intranasal) in September 2022. This FDA-approved nasal-spray flu vaccine for individuals aged 2 to 49 is administered through a needle-free nasal spray. It is available in trivalent or quadrivalent formulations, providing a live attenuated influenza vaccine (LAIV) covered by most health insurance plans and the vaccines for children program.

Major companies operating in the quadrivalent market are prioritizing safer and innovative vaccine delivery technologies, such as nanoparticle technology, to boost their revenues. This nanoparticle technology mimics the virus's outer structure using virus-like particles (VLPs) without containing any live genetic material, which enhances both safety and immune response. For example, in March 2024, Cadila Pharmaceuticals, a pharmaceutical company based in India, launched its advanced Quadrivalent Influenza Vaccine, designed to provide protection against four distinct strains of the influenza virus, including two A strains (H1N1 and H3N2) and two B strains. This quadrivalent formulation improves the vaccine's efficacy by targeting a broader range of circulating influenza viruses, making it particularly effective during flu seasons. The aQIV aims to stimulate a strong immune response, thereby reducing the incidence of influenza-related morbidity and mortality. Its development highlights ongoing efforts to enhance public health outcomes in response to evolving viral strains.

In February 2023, China-based biotechnology company Clover Biopharmaceuticals Ltd. entered into a partnership with Adimmune Corporation, a Taiwan-based biopharmaceutical company. This collaboration leverages Adimmune's manufacturing and distribution expertise in providing essential vaccines to Asian populations. Clover aims to strengthen its position as a premier respiratory vaccine franchise and enhance synergies with ongoing COVID-19 vaccine commercialization. As part of this collaboration, Clover will distribute Adimmune's AdimFlu-S (QIS), the only imported quadrivalent influenza vaccination authorized in mainland China, utilizing its established commercial infrastructure.

Major companies operating in the quadrivalent market include AstraZeneca Plc, Serum Institute of India Private Limited, Sanofi S.A., GlaxoSmithKline Plc, CSL Limited, Bharat Biotech International Limited, Hualan Biological Engineering Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Pfizer Inc., Bio Med Pvt. Ltd., Walvax Biotechnology Co. Ltd., Chongqing Zhifei Biological Products Co. Ltd., Emergent BioSolutions Inc., Biological E. Limited, GSK Biologicals SA, Institute of Vaccines and Biological Products Chinese Academy of Medical Sciences, Wuhan Institute of Biological Products Co. Ltd., Beijing Tian Tan Biological Products Co. Ltd., Shanghai Zhijiang Bio-pharm Co. Ltd., Bio Farma, Butantan Institute, Pasteur Institute of India, China National Biotec Group Co. Ltd. (CNBG)

North America was the largest region in the quadrivalent market in 2024. The regions covered in the quadrivalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the quadrivalent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A quadrivalent vaccine stimulates the immune system to respond to distinct antigens, typically targeting four different viruses or bacteria. In the context of influenza, a quadrivalent vaccine is designed to provide protection against four specific flu viruses, including two type A and two type B viruses.

The primary types of quadrivalent vaccines include intradermal shots, intramuscular injections, and nasal sprays. An intradermal shot involves injecting the vaccine between the epidermis and hypodermis, the top and bottom layers of the skin, as defined by the Center for Disease Control (CDC). These vaccines are formulated using various technologies, including conjugated, live, inactivated, recombinant, toxoid, and others, aiming to immunize against a range of diseases such as cancer, hepatitis, pneumococcal disease, COVID-19, influenza, human papillomavirus, meningococcal disease, polio, rotavirus, and others affecting both pediatric and adult age groups. Distribution channels for these vaccines include hospitals, pharmacies, government suppliers, and other outlets.

The quadrivalent market research report is one of a series of new reports that provides quadrivalent market statistics, including quadrivalent industry global market size, regional shares, competitors with a quadrivalent market share, detailed quadrivalent market segments, market trends and opportunities, and any further data you may need to thrive in the quadrivalent industry. This quadrivalent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The quadrivalent market consists of sales of afluria quadrivalent, fluarix quadrivalent, flublok quadrivalent, fluzone quadrivalent (influenza virus vaccine), flulaval quadrivalent, flucelvax quadrivalent, menactra and menveo. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.